Compare Amphastar Pharmaceuticals Inc (AMPH) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Cigna Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.35 (market cap $826.08M), while Cigna Corp trades at $301.46 (market cap $77.63B). The key difference: Cigna Corp is far larger — about 94× Amphastar Pharmaceuticals Inc's market cap, and Cigna Corp pays a 2.13% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CI | |
|---|---|---|
Market Cap | $826.08M | $77.63B |
Sector | Health | Health |
52-Week High | $30.81 | $311.00 |
52-Week Low | $16.87 | $244.41 |
Enterprise Value | $1.22B | $100.73B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Cigna (CI) trades at $293.46, up 0.57% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.44 and P/S of 0.28. Recent news highlights strategic initiatives, including AI integration in pharmacy services. The current price is near the consensus price target of $339.82, indicating potential upside.
The outlook for CI is positive, driven by earnings momentum, a favorable analyst consensus, and strategic growth investments. Key risks include regulatory challenges, as seen in a recent lawsuit in Tennessee, and competitive pressures in the healthcare sector. Net cash flow turned negative in 2025, which warrants monitoring. The stock presents a value opportunity with a solid dividend, but investors should weigh execution risks against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
